Memantin Stada

Memantine Hydrochloride, the active ingredient in Memantin Stada, is a NMDA receptor antagonist presented as a tablet for oral use. It treats moderate to severe Alzheimer’s disease in adult patients who have been diagnosed with progressive cognitive decline.

GNH USA supplies Memantin Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantin Stada is an NMDA‑receptor antagonist indicated for conditions within the Alzheimer’s disease spectrum.

Alzheimer’s disease (moderate to severe): Improves cognition and daily functioning in patients with diagnosed moderate to severe disease. Alzheimer’s disease (mild to moderate): May be added to existing therapy to support symptom control. Behavioral disturbances in Alzheimer’s disease: Can help reduce agitation and aggression associated with the condition.

Memantin Stada may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Dizziness - Headache - Constipation - Fatigue - Confusion - Hypertension

Serious or Rare Side Effects: - Seizures - Severe allergic reactions (e.g., rash, angioedema) - Stevens‑Johnson syndrome - Hepatic injury - Cardiac arrhythmias - Psychotic episodes

Before initiating therapy, clinicians should consider several safety aspects.

Renal impairment: Adjust dose or monitor renal function closely. History of seizures: Observe for increased seizure activity. Cardiovascular disease: Monitor blood pressure and heart rate. Concurrent NMDA antagonists: Avoid combined use to prevent additive neurotoxicity. Pregnancy and lactation: Safety not established; weigh benefits against potential risks. Store at room temperature: Keep in original packaging, protect from moisture and direct sunlight.

Memantin Stada can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Amantadine: Additive NMDA antagonism may increase neurotoxicity. - Ketamine: Combined use can exacerbate neuropsychiatric effects. - Strong anticholinergic agents: May diminish therapeutic benefit.

Moderate Interactions (Monitor Closely): - Antihypertensive drugs: Potential for enhanced hypotensive effect. - Diuretics: Monitor electrolyte balance. - Other CNS depressants: May increase sedation or dizziness.